Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 16, 2016 - Issue 6
Submit an article Journal homepage
244
Views
2
CrossRef citations to date
0
Altmetric
Review

Economics of ramucirumab for metastatic colorectal cancer

Simon B. ZeichnerDivision of Hematology & Oncology, Winship Cancer Institute at Emory University, Atlanta, GA, USACorrespondence[email protected]
View further author information
,
Christine G. KohnHartford Hospital Evidence-Based Practice Center, University of Saint Joseph School of Pharmacy & UConn, Hartford, CT, USAView further author information
&
Daniel A. GoldsteinDivision of Hematology & Oncology, Winship Cancer Institute at Emory University, Atlanta, GA, USA;Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, IsraelView further author information
Pages 733-745 | Received 31 Jul 2016, Accepted 07 Nov 2016, Published online: 25 Nov 2016

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Hanrui Zheng, Zhou Qin, Xingjian Qiu, Mei Zhan, Feng Wen & Ting Xu. (2020) Cost-effectiveness analysis of ramucirumab treatment for patients with hepatocellular carcinoma who progressed on sorafenib with α-fetoprotein concentrations of at least 400 ng/ml. Journal of Medical Economics 23:4, pages 347-352.
Read now

Articles from other publishers (1)

Guido Giordano, Pietro Parcesepe, Giuseppina Bruno, Annamaria Piscazzi, Vincenzo Lizzi, Andrea Remo, Massimo Pancione, Mario Rosario D’Andrea, Elena De Santis, Luigi Coppola, Michele Pietrafesa, Alberto Fersini, Antonio Ambrosi & Matteo Landriscina. (2021) Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era. International Journal of Molecular Sciences 22:14, pages 7717.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.